Researchers have identified RUNX1C, an RNA isoform that drives chemoresistance in acute myeloid leukemia (AML). The study, ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

Researchers have developed a novel cancer therapy using Salmonella typhimurium to deliver an oncolytic virus directly into ...

A novel mRNA-based vaccine encoding tumor-specific neoantigens significantly enhanced anti-PD-1 therapy in gastric cancer ...

New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB ...

The Phase 3 EV-303 (KEYNOTE-905) trial shows PADCEV™ (enfortumab vedotin) plus KEYTRUDA™ (pembrolizumab) is the first and only regimen to significantly extend event-free and overall survival when used ...

Birelentinib has received FDA Fast Track Designation for relapsed/refractory chronic lymphocytic leukemia (CLL) or small ...

A Penn Medicine study has shown that tailoring chemotherapy doses based on genetic testing can significantly improve safety for gastrointestinal (GI) cancer patients. Screening for variants in two key ...